Holen Sie sich die Stockscreener-App
812.64
0.87%
-6.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly doubles down on Mounjaro despite rising competition in Brazil - Valor International
The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa - Nasdaq
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly - Stocktwits
Erste Group upgrades Eli Lilly stock rating to Buy after strong H1 results - Investing.com Canada
Top Stock Reports for Apple, Eli Lilly & Visa - Nasdaq
Eli Lilly and Company Strengthens Presence Among S&P 500 Companies - Kalkine Media
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Down 44%, Should You Buy the Dip on Viking Therapeutics? - The Motley Fool
Lilly Wants To Know: What Does Chronic Illness Really Look Like? 10/13/2025 - MediaPost
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years - Yahoo Finance
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025) - 24/7 Wall St.
Eli Lilly Opens R&D Incubator for Life Sciences Startups - San Diego Business Journal
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa - Reuters
Should Omvoh’s Clinical Success and Earnings Optimism Prompt Action from Eli Lilly (LLY) Investors? - simplywall.st
Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus? - Yahoo Finance
The Goldman Sachs Group Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Insider Sales Surge: Block, Eli Lilly, Strategy, P&G, Dell - TipRanks
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Should Investors Buy Eli Lilly Stock? - The Globe and Mail
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and more - Endpoints News
Gunderson Capital Management Inc. Increases Position in Eli Lilly and Company $LLY - MarketBeat
Seeking Safe Havens: Why Pfizer and Eli Lilly Are Top Market Picks Now? - NAI500
Major Shareholder Sells Millions in Eli Lilly Stock! - TipRanks
Eli Lilly (LLY): Revisiting Valuation After Recent Share Price Gains - simplywall.st
Lilly Endowment sells Eli Lilly shares worth $9.04 million - Investing.com
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$9.04 Million in Common Stock - 富途牛牛
Lilly Endowment unloads about $600 million in Eli Lilly stock during early October - Sherwood News
Eli Lilly’s New Study on Weight Reduction Drugs: A Potential Market Game-Changer? - TipRanks
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
Next Medicine Deal After Pfizer? Analysts, Shares Point to AstraZeneca, Eli Lilly - Money US News.com
WHO Arm Seeks Talks with Novo Nordisk, Eli Lilly on Expanding Access to Weight-loss Drugs - MarketScreener
Shape’s former CSO picks up tech role at Moderna; Lilly reels in Peter Marks - Endpoints News
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now - The Globe and Mail
Verde Servicos Internacionais S.A. Purchases New Position in Eli Lilly and Company $LLY - MarketBeat
Baxter Bros Inc. Lowers Stock Position in Eli Lilly and Company $LLY - MarketBeat
Major Shareholder Cashes Out Millions in Eli Lilly Stock! - TipRanks
LILLY ENDOWMENT INC Reduces Stake in Eli Lilly and Co - GuruFocus
Eli Lilly (LLY) Gains As Market Dips: What You Should Know - Yahoo Finance
Lilly Endowment sells Eli Lilly & Co (LLY) shares for $86.2m - Investing.com Canada
A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is. - MSN
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions - FinancialContent
Lobbying Update: $10,000 of ELI LILLY & COMPANY lobbying was just disclosed - Quiver Quantitative
Eli Lilly Completes Phase 1 Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
US-based Eli Lilly to invest $1 billion in India - The Indian EYE
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? - Nasdaq
Eli Lilly and Company ($LLY) Stock: Appoints Former FDA Biologics Head Peter Marks as Senior VP of Molecule Discovery - CoinCentral
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market - Yahoo Finance
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $925 From $825, Maintains Overweight Rating - MarketScreener
Notis McConarty Edward Acquires 1,424 Shares of Eli Lilly and Company $LLY - MarketBeat
Capital Management Associates Inc Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Dempze Nancy E Increases Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Richmond United to vacate West Creek soccer complex, make way for $5B Eli Lilly pharma facility - Richmond BizSense
Eli Lilly To Invest $1 Billion In India, Boosts Hyderabad’s Pharma Sector - indica News
US pharma company: Eli Lilly to invest USD 1 billion in India; Piyush Goyal reacts - ET Now
Major Shareholder Cashes In on Eli Lilly & Co Stock! - TipRanks
Eli Lilly’s SWOT analysis: stock poised for growth amid obesity market boom - Investing.com
Judge Drops Eli Lilly’s Suit Over Compounded Zepbound, Mounjaro - Bloomberg Law News
Lilly Endowment sells $22.7 million in Eli Lilly shares - Investing.com
Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery - MarketScreener
Is Eli Lilly Stock A Buy After Surging On Trump's Drug-Pricing Plans? - Investor's Business Daily
Lilly outlines $1bn India manufacturing expansion - European Pharmaceutical Review
Guggenheim Maintains Eli Lilly and (LLY) Buy Recommendation - Nasdaq
Eli Lilly Stays On Track With Wall Street Projections - Finimize
0.14%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):